Montelukast in allergic diseases beyond asthma

Salvatore Leonardi, Giuseppe Marchese, Gian Luigi Marseglia, Mario La Rosa

Research output: Contribution to journalArticlepeer-review


Allergic diseases include a variety of different illnesses (rhinitis, conjunctivitis, asthma, urticaria, and dermatitis) in which the physiological and pathological basis is the release of chemical mediators such as histamine; platelet-activating factor; metabolites of arachidonic acid; and chemotactic factors from mastocytes, basophils, and eosinophils. The numerous drugs used for allergy treatment now include the new pharmacologic category of cysteinyl leukotriene (LT) antagonists. LTs are released from eosinophils, mast cells, and macrophages, interacting functionally in allergic reactions against a background of an imbalance between T-cell clones and resulting in preferential cytokine production following the T-helper 2 profile. Anti-LTs also have been used successfully by some authors to control rhinitis, atopic dermatitis, and urticaria, although additional controlled testing will be required, these applications broaden the possible range of treatments for allergic disease in all its many aspects.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalAllergy and Asthma Proceedings
Issue number3
Publication statusPublished - May 2007


  • Allergic diseases
  • Allergic rhinitis
  • Atopic dermatitis
  • Chronic urticaria
  • Cysteinyl leukotriene antagonists
  • Montelukast
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'Montelukast in allergic diseases beyond asthma'. Together they form a unique fingerprint.

Cite this